Azithromycin for mild-to-moderate COVID-19

Lancet Respir Med. 2021 Oct;9(10):e99. doi: 10.1016/S2213-2600(21)00379-9. Epub 2021 Sep 9.

Authors

Jigar Patel¹, Ivan Berezowski², Ahmed Abdelmonem², Dania Taylor², Ali Pourmand²

Affiliations

¹ International Medicine Program, The George Washington University School of Medicine and Health Sciences, Washington, DC 20037, USA. Electronic address: jigar.r.patel@outlook.com.
² International Medicine Program, The George Washington University School of Medicine and Health Sciences, Washington, DC 20037, USA.

No abstract available

Publication types

Letter
Comment

MeSH terms

Azithromycin*
COVID-19 Drug Treatment*
Humans
SARS-CoV-2

Substances

Azithromycin